VA Drug Price Reporting: The Manufacturer’s Data Behind the Federal Ceiling

VA drug price reporting can turn non-FAMP calculation errors into higher federal ceiling prices and government overcharges. If you work in pharmaceutical pricing, finance or contract administration, you may know why the sales data inside the company differs from the number sent to VA. That difference can follow a drug all the way to the government’s purchase.

The VA Office of Inspector General’s September 2024 pharmaceutical pricing report examined reviews completed in fiscal years 2022 and 2023. It described errors inside a manufacturer’s government pricing system, additional errors found during review, and corrections to earlier pricing records. For an insider, the question is concrete: did the price reported to VA reflect the data the manufacturer actually held?

What Does Non-FAMP Do in a VA Drug Contract?

Non-FAMP means non-federal average manufacturer price, the manufacturer-reported figure used to calculate a covered drug’s annual federal ceiling price. Under the Veterans Health Care Act, manufacturers submit that data annually, and VA Pharmacy Benefits Management Services uses it to calculate the ceiling. The ceiling must be at least 24 percent below non-FAMP.

The covered buyers are known as the Big 4: VA, the Department of Defense, the Public Health Service and the Coast Guard. VA administers the pharmaceutical Federal Supply Schedule, but the purchasing reaches across those agencies.

Covered drugs include commercially sold innovator drugs approved under a new drug application and biological products approved under a biological licensing agreement. The manufacturer’s pharmaceutical pricing agreement supplies updated pricing and non-FAMP data to VA. The report explains the payment stakes: a manufacturer that does not enter into a master agreement or offer a covered drug on the schedule at or below the statutory ceiling cannot receive payment for that drug from the Big 4 agencies, recipients of Public Health Service Act funds or state Medicaid plans.

The National Drug Code connects that input to a particular product configuration. The Food and Drug Administration assigns a unique code to each package size, strength and volume, which is why reviewers analyzed codes rather than treating every version of a drug as one item. A product name alone leaves out the detail needed to connect the calculation to the sale.

How Non-FAMP Calculation Errors Reach the Government Price

An error in the manufacturer’s calculation can produce an inflated ceiling before anyone sends the government an invoice. Four of the Inspector General’s reviews involved disclosed calculation errors affecting 306 covered drug codes. The financial consequence was already in the sales, because the Inspector General measured the errors as overcharges to the government.

Most of the errors concerned a manufacturer and another company in which it held a majority stake. According to the manufacturer, several errors in its government pricing system caused the incorrect calculations for both companies. The Inspector General expanded its reviews after finding additional errors beyond those disclosed.

For the majority shareholder, the manufacturer’s estimated overcharges were $4,359,123. The Inspector General calculated $6,477,028. We see a concrete reason to look beyond the company’s first account of what went wrong: even its own disclosure left more for reviewers to find.

The manufacturer’s response included routine system monitoring to ensure the calculations captured all relevant data. It corrected the affected non-FAMPs, the Inspector General accepted the restatements, and reviewers verified that VA updated its records for the affected periods. The repair reached the data captured by the pricing system, as well as the numbers it produced.

To calculate overcharges, the Inspector General compared prices in manufacturers’ Federal Supply Schedule sales data with the ceilings that should have applied, then used the quantities sold. That comparison ties the calculation problem to actual government purchases. If you saw a transaction category disappear from a calculation or an internal report identify missing sales data, we would want to understand how that change affected the reported price and the sales made under it.

Why a Restatement Can Reach Earlier Purchases

A non-FAMP restatement can change the historical pricing record because an earlier year’s price can affect a current price. The Inspector General gave manufacturers time to restate submissions for drugs already on contract, then evaluated their calculation methods and results. VA’s pricing office recalculated the related ceilings and updated historical records, while contracting officers modified the contracts.

That sequence gives a correction a longer reach than the next annual submission. The original calculation, the restated calculation and the ceiling used for the affected period belong in the same comparison. The sales file then shows which purchases used the price that needed correction.

For someone who worked on the restatement, the useful questions concern its reach: which drug codes changed, which reporting periods changed, and which government prices changed with them? We connect the answers to the sales and billing records for those periods. The history matters because the government may already have bought the drugs at the earlier price.

What the Public Review Shows About the Manufacturer’s Records

VA’s Inspector General withheld its individual manufacturer reviews because they contained protected commercial information. Its public summary uses numbers in place of manufacturer names. That makes the internal calculation and the response to an error especially important to a person who actually worked with them.

Reviewers examined the reported calculations and obtained further documentation from manufacturers. The public account shows how a disclosure could lead to a wider examination of the pricing system and its results.

Non-FAMP and the Price Reductions Clause Follow Different Comparisons

Non-FAMP reporting supplies the data for a statutory ceiling. The Price Reductions Clause ties the government’s price to a commercial customer or customer category chosen in the contract. When that customer’s price falls, the government must receive the corresponding reduction. The Inspector General examined these obligations separately, even where both affected government drug prices.

For a pricing employee, the distinction determines which data explains the charge. The non-FAMP inquiry follows the calculation and submission for the covered drug. The commercial-discount inquiry follows the agreed customer relationship, the customer’s price and the government price that should have changed with it.

What a Pricing Insider Sees Behind the Reported Price

Useful proof connects the manufacturer’s underlying pricing data, its submission to VA and the affected government purchases. What happened after an internal error report matters alongside the original calculation. If you saw a warning about omitted data, worked on a restatement or were told to leave a known discrepancy in place, we can examine those decisions with you.

A study of occupational fraud, Unique Characteristics of Management Override Fraud Cases, published in the Journal of Forensic and Investigative Accounting in 2019, compared cases involving missing controls with cases in which management overrode existing controls. It found that organizations with audit functions, anti-fraud policies and codes of conduct could still suffer fraud through people overriding those protections. For a pricing operation, we want to know how the people responsible responded when a control exposed a problem. The paper puts management’s position plainly:

A False Claims Act case can address a company knowingly using false pricing records to get the government to overpay. Our work with a pricing insider connects what the company knew to what it reported and what the government paid. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Why the Reported Price Was Wrong

If you know which data went missing or how a pricing warning was handled, speak to one of our whistleblower experts about how the reported price went wrong. We work beside you to connect the calculations, decisions and government purchases into your strongest drug pricing whistleblower case. We stay with you through the whole journey and bring in pharmaceutical pricing whistleblower lawyers who understand federal purchasing.